UGT2B17 and posterior cortical atrophy: We assessed (1) the relationship between UGT2B17 protein expression and clinico-pathological factors in a well-characterised cohort of 239 patients with localised disease, (2) evaluated whether UGT2B17 expression is associated with changes in the circulating steroid metabolome and (3) appraised whether UGT2B17 is an independent marker associated with the risk of PCa progression following primary curative treatment by RP.